Anna Tavakkoli1, Henry D Appelman2, David G Beer3, Chaitra Madiyal4, Maryam Khodadost5, Kimberly Nofz5, Val Metko5, Grace Elta6, Thomas Wang4, Joel H Rubenstein7. 1. Barrett's Esophagus Program, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan. Electronic address: annatav@med.umich.edu. 2. Department of Pathology, University of Michigan, Ann Arbor, Michigan. 3. Department of Thoracic Surgery, University of Michigan, Ann Arbor, Michigan. 4. Barrett's Esophagus Program, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan. 5. Barrett's Esophagus Program, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan; Division of Gastroenterology, Veterans Affairs Hospital, Ann Arbor, Michigan. 6. Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan. 7. Barrett's Esophagus Program, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan; Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
Abstract
BACKGROUND & AIMS: Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC). Guidelines recommend that patients with nondysplastic BE (NDBE) undergo surveillance endoscopy every 3-5 years. We aimed to identify factors associated with surveillance endoscopy of patients with NDBE and identify trends in appropriate surveillance endoscopy of NDBE at a large tertiary care center. METHODS: We performed a retrospective analysis of data from a Barrett's Esophagus Registry, identifying patients with NDBE who underwent endoscopy in 2002 or later. We identified patients with NDBE and collected data on length of BE segment, esophageal lesions, demographic features, medications, histology findings, comorbidities, development of EAC, and dates of follow-up endoscopies. We defined appropriate surveillance as 3-5 years between 2nd and 3rd endoscopies, over-utilizers as patients who had less than 3 years between their 2nd and 3rd endoscopies, under-utilizers as patients who had more than 5 years between their 2nd and 3rd endoscopies; and never-surveilled as patients who never received a 2nd endoscopy. The primary outcomes were effects of patient factors, year, and referring providers on appropriateness of surveillance intervals. RESULTS: We identified 477 patients with NDBE. Only 15.9% had appropriate surveillance; 37.9% were over-utilizers 15.7% were under-utilizers and 30.4% were never surveilled. Patients were less likely to be over-surveilled if their primary care physician referred them for their 3rd endoscopy instead of a gastroenterologist (adjusted odds ratio, 0.51; 95% CI, 0.27-0.95). Male patients or those with an increased number of comorbidities were more likely to be under-surveilled or never-surveilled, whereas patients with long BE segment were more likely to be over-surveilled. CONCLUSIONS: In a retrospective analysis of data from a registry of patients with BE, we found that less than 16% receive appropriate surveillance for NDBE. A primary care provider in the same health system as the endoscopy clinic reduced risk of over-surveillance. This could reflect better coordination of care between specialists and primary care providers.
BACKGROUND & AIMS: Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC). Guidelines recommend that patients with nondysplastic BE (NDBE) undergo surveillance endoscopy every 3-5 years. We aimed to identify factors associated with surveillance endoscopy of patients with NDBE and identify trends in appropriate surveillance endoscopy of NDBE at a large tertiary care center. METHODS: We performed a retrospective analysis of data from a Barrett's Esophagus Registry, identifying patients with NDBE who underwent endoscopy in 2002 or later. We identified patients with NDBE and collected data on length of BE segment, esophageal lesions, demographic features, medications, histology findings, comorbidities, development of EAC, and dates of follow-up endoscopies. We defined appropriate surveillance as 3-5 years between 2nd and 3rd endoscopies, over-utilizers as patients who had less than 3 years between their 2nd and 3rd endoscopies, under-utilizers as patients who had more than 5 years between their 2nd and 3rd endoscopies; and never-surveilled as patients who never received a 2nd endoscopy. The primary outcomes were effects of patient factors, year, and referring providers on appropriateness of surveillance intervals. RESULTS: We identified 477 patients with NDBE. Only 15.9% had appropriate surveillance; 37.9% were over-utilizers 15.7% were under-utilizers and 30.4% were never surveilled. Patients were less likely to be over-surveilled if their primary care physician referred them for their 3rd endoscopy instead of a gastroenterologist (adjusted odds ratio, 0.51; 95% CI, 0.27-0.95). Male patients or those with an increased number of comorbidities were more likely to be under-surveilled or never-surveilled, whereas patients with long BE segment were more likely to be over-surveilled. CONCLUSIONS: In a retrospective analysis of data from a registry of patients with BE, we found that less than 16% receive appropriate surveillance for NDBE. A primary care provider in the same health system as the endoscopy clinic reduced risk of over-surveillance. This could reflect better coordination of care between specialists and primary care providers.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: John A Evans; Dayna S Early; Norio Fukami; Tamir Ben-Menachem; Vinay Chandrasekhara; Krishnavel V Chathadi; G Anton Decker; Robert D Fanelli; Deborah A Fisher; Kimberly Q Foley; Joo Ha Hwang; Rajeev Jain; Terry L Jue; Khalid M Khan; Jenifer Lightdale; Phyllis M Malpas; John T Maple; Shabana F Pasha; John R Saltzman; Ravi N Sharaf; Amandeep Shergill; Jason A Dominitz; Brooks D Cash Journal: Gastrointest Endosc Date: 2012-12 Impact factor: 9.427
Authors: Nancy N Baxter; Rinku Sutradhar; Qing Li; Corinne Daly; Gladys N Honein-AbouHaidar; Devon P Richardson; Lisa Del Giudice; Jill Tinmouth; Lawrence Paszat; Linda Rabeneck Journal: Am J Gastroenterol Date: 2017-02-28 Impact factor: 10.864
Authors: Lesly A Dossett; Janella N Hudson; Arden M Morris; M Catherine Lee; Richard G Roetzheim; Michael D Fetters; Gwendolyn P Quinn Journal: CA Cancer J Clin Date: 2016-10-11 Impact factor: 508.702
Authors: Jennifer R Kramer; Mohammad H Shakhatreh; Aanand D Naik; Zhigang Duan; Hashem B El-Serag Journal: JAMA Intern Med Date: 2014-03 Impact factor: 21.873
Authors: Joel H Rubenstein; Richard R Evans; Jennifer A Burns; Maria E Arasim; Ji Zhu; Akbar K Waljee Journal: Gastroenterology Date: 2021-12-20 Impact factor: 22.682
Authors: Elissa M Ozanne; Elisabeth R Silver; Sameer D Saini; Joel H Rubenstein; Iris Lansdorp-Vogelaar; Nicole Bowers; Sarah Xinhui Tan; John M Inadomi; Chin Hur Journal: Am J Gastroenterol Date: 2021-08-01 Impact factor: 12.045